InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:15 August 2023

This Phase II trial is evaluating how safe and effective a new drug (KER-050) is alone, and in combination with targeted therapy (ruxolitinib) in people with myelofibrosisA Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis

Clinical summary

Summary

This is a non-randomised, open-label trial with four experimental arms. In experimental arm 1a (dose escalation), participants will receive KER-050 monotherapy, administered via subcutaneous injection (SC) every 4 weeks, for up to 13 cycles. In experimental arm 1b (dose escalation), participants will receive KER-050, administered SC, every 4 weeks, for up to 13 cycles, in combination with standard of care ruxolitinib, administered orally twice daily. In experimental arm 2a (dose expansion), participants will receive KER-050 monotherapy, administered SC, every 4 weeks, for up to 13 cycles. In experimental arm 2b, participants will receive KER-050, administered SC every 4 weeks for up to 13 cycles, in combination with standard of care ruxolitinib, administered orally twice daily.

Age

People18+

Phase

II

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Keros Therapeutics

Scientific Title

A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Exclusion

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had a certain type of treatment or surgical procedure.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more